Intellia Therape Stock Price, News & Analysis

Intellia Therapeutics (NASDAQ:NTLA) announced the FDA's acceptance of the IND application for NTLA-5001, its first ex vivo CRISPR-engineered therapy targeting Wilms’ Tumor 1 (WT1) for acute myeloid leukemia (AML). This milestone paves the way for a Phase 1/2a clinical study, expected to start patient screening by year-end, focusing on AML patients post-first-line therapy. The therapy aims to improve the five-year survival rate, currently below 30%. The study will involve up to 54 participants across two dosing categories, assessing safety and anti-tumor efficacy.

Intellia Therapeutics (NASDAQ:NTLA), a clinical-stage genome editing company, will participate in two virtual healthcare investor conferences in September 2021. The first will be at the Wells Fargo Healthcare Conference on September 9 at 10:40 am ET, followed by the H.C. Wainwright 23rd Annual Global Investment Conference on September 13 at 7:00 am ET. Live webcasts of the presentations will be available on Intellia's website, with replays accessible for 14 days post-event. Intellia focuses on curative therapeutics powered by CRISPR/Cas9 technology.

Intellia Therapeutics has made significant strides in its CRISPR gene-editing programs, with promising interim Phase 1 data for NTLA-2001 showing a maximum 96% reduction in serum TTR levels for ATTR amyloidosis. The company is poised to initiate Phase 1 trials for NTLA-2002 and NTLA-5001 this year. Financially, Intellia ended Q2 2021 with $551.3 million in cash and raised an additional $648.1 million from a follow-on offering. Despite a net loss of $68.8 million, Intellia's strong financial position supports ongoing and future development efforts.

Intellia Therapeutics (NASDAQ:NTLA) will present its Q2 2021 financial results and operational highlights on August 5, 2021, at 8 a.m. E.T. The conference call will provide insights into its progress in developing CRISPR/Cas9-based therapeutics. Interested participants can join via U.S. or international dialing, with a live webcast available. A replay will be accessible on Intellia's website starting noon E.T. on the same day. The company focuses on curative therapies using both in vivo and ex vivo genome editing techniques.

Intellia Therapeutics (NASDAQ:NTLA) has completed a public offering of 4,758,620 shares at $145.00 each, raising approximately $690 million, following the full exercise of the underwriters' option for 620,689 additional shares. The offering was managed by Goldman Sachs, Jefferies, SVB Leerink, and Barclays. Shares were offered under a shelf registration statement effective with the SEC. This capital is expected to support the development of Intellia's CRISPR/Cas9-based therapeutics. The press release includes forward-looking statements subject to market uncertainties.

Intellia Therapeutics (NASDAQ:NTLA) announced the pricing of a public offering of 4,137,931 shares at $145.00 per share, aiming to raise approximately $600 million before expenses. The offering includes a 30-day option for underwriters to purchase up to an additional 620,689 shares. The offering is set to close around July 2, 2021, subject to conditions. Goldman Sachs, Jefferies, SVB Leerink, and Barclays are the joint managers for this offering, which is conducted under an effective SEC shelf registration statement.

Intellia Therapeutics (NASDAQ:NTLA) announced a public offering of $400 million in common stock, with an option for underwriters to purchase an additional 15%. The company aims to utilize proceeds for advancing its CRISPR/Cas9 genome editing technology. Goldman Sachs & Co. LLC, Jefferies, SVB Leerink, and Barclays are joint book-running managers for the offering. The offering is contingent on market conditions and may change. The shares will be sold under an effective registration statement filed with the SEC, ensuring compliance with securities laws.

Intellia Therapeutics and Regeneron Pharmaceuticals announced promising interim results from a Phase 1 trial of NTLA-2001 for treating hereditary transthyretin amyloidosis (ATTRv-PN). The single 0.3 mg/kg dose led to an impressive 87% mean reduction in serum TTR levels, with a maximum reduction of 96% observed by day 28. The treatment showed a favorable safety profile, with no serious adverse events reported among the first six patients. Data was published in The New England Journal of Medicine and presented at the Peripheral Nerve Society Annual Meeting. Future expansions of the trial are planned.

Intellia Therapeutics (NTLA) announced promising interim results from its Phase 1 trial of NTLA-2001, the first in vivo CRISPR genome editing therapy for hereditary transthyretin amyloidosis with polyneuropathy. A 0.3 mg/kg dose led to an 87% mean reduction in serum TTR levels, peaking at 96% by day 28. The treatment exhibited a favorable safety profile with no serious adverse events in the first six patients. These findings, published in The New England Journal of Medicine, highlight NTLA-2001's potential as a single-dose therapy that could transform treatment outcomes for this serious condition.